1. Dominantly inherited Alzheimer's disease in Latin America: Genetic heterogeneity and clinical phenotypes
- Author
-
Michelle Doering, Víctor Sánchez, Francisco Lopera, Yan Li, Ana Luisa Sosa, Ricardo F. Allegri, Daisy Acosta, Christian Schenk, Ricardo Nitrini, Jorge J. Llibre-Guerra, Ellen Ziegemeier, Joyce Benevides-Lima, Norberto Anizio Ferreira-Frota, Juan J. Llibre-Rodriguez, Patricio Chrem Mendez, Eric McDade, Ezequiel Surace, Carmen Alaez-Verson, Maria I. Behrens, Laura Ramírez, Alberto Tellez, John C. Morris, Randall J. Bateman, Erika-Mariana Longoria, Karol Carrillo-Sánchez, Luis Leonardo Flores-Lagunes, Ivonne Z. Jimenez-Velazquez, and Leonel T. Takada
- Subjects
0301 basic medicine ,Latin Americans ,Epidemiology ,Population ,Diad ,Disease ,Biology ,Article ,Genetic Heterogeneity ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,0302 clinical medicine ,Developmental Neuroscience ,Alzheimer Disease ,Humans ,Genetic Predisposition to Disease ,education ,Genes, Dominant ,education.field_of_study ,Genetic heterogeneity ,Health Policy ,Psychiatry and Mental health ,Latin America ,Phenotype ,030104 developmental biology ,Mutation ,Biomarker (medicine) ,Observational study ,Neurology (clinical) ,Geriatrics and Gerontology ,030217 neurology & neurosurgery ,Demography ,Founder effect - Abstract
Introduction A growing number of dominantly inherited Alzheimer's disease (DIAD) cases have become known in Latin American (LatAm) in recent years. However, questions regarding mutation distribution and frequency by country remain open. Methods A literature review was completed aimed to provide estimates for DIAD pathogenic variants in the LatAm population. The search strategies were established using a combination of standardized terms for DIAD and LatAm. Results Twenty-four DIAD pathogenic variants have been reported in LatAm countries. Our combined dataset included 3583 individuals at risk; countries with highest DIAD frequencies were Colombia (n = 1905), Puerto Rico (n = 672), and Mexico (n = 463), usually attributable to founder effects. We found relatively few reports with extensive documentation on biomarker profiles and disease progression. Discussion Future DIAD studies will be required in LatAm, albeit with a more systematic approach to include fluid biomarker and imaging studies. Regional efforts are under way to extend the DIAD observational studies and clinical trials to Latin America.
- Published
- 2020
- Full Text
- View/download PDF